Program
cizutamig
Also written as “Cizutamig” and “EMB-06”.
Its studies are mostly in Myasthenia Gravis · Lupus Erythematosus, Systemic · Milk Hypersensitivity · Multiple Myeloma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 42 open or running | phase 1since Sep 23, 2025 | Sep 23, 2025 | Dec 2027phase 1 · NCT07215650 |
| Shanghai EpimAb Biotherapeutics | 10 open or running | phase 2since Jan 28, 2021 | Jan 28, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 28, 2021First study: phase 2 study in RecurrenceNew to Shanghai EpimAb BiotherapeuticsShanghai EpimAb Biotherapeutics · NCT04735575 · 40 enrolled · Australia, China
- Sep 23, 2025UCB's first studies: 2 phase 1 studiesNew to UCBUCB · NCT07215663, NCT07215650
- Nov 13, 2025Phase 1 study in Healthy Participants StudyUCB · NCT07236411 · 24 enrolled · Australia
- Dec 23, 2025Phase 1 study in Hypersensitivity, ImmediateUCB · NCT07408869 · Australia
Ahead
- Dec 2027Primary completion: phase 1 study in Myasthenia GravisUCB · NCT07215650
- Dec 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicUCB · NCT07215663
TargetBeta
“A tetravalent, bispecific antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | kelonia-therapeutics-inc | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07408869Hypersensitivity, Immediate · Australia | 1 | Withdrawn | UCB | Dec 2026 | 0 |
| NCT07236411Healthy Participants Study · Australia | 1 | Completed | UCB | Apr 16, 2026 | 24 |
| NCT07215650Myasthenia Gravis · China | 1 | Recruiting | UCB | Dec 2027 | 44 |
| NCT07215663Lupus Erythematosus, Systemic · China | 1 | Recruiting | UCB | Dec 2027 | 47 |
| NCT04735575Recurrence · Australia, China | 2 | Terminated | Shanghai EpimAb Biotherapeutics | Aug 20, 2024 | 40 |
How it is read
Names in the registry
- “Cizutamig”, 3 entries
- “cizutamig”, 1 entry
- “EMB-06”, 1 entry
Conditions, from the studies’ own filings
- Myasthenia Gravis, 1 study
- Lupus Erythematosus, Systemic, 1 study
- Milk Hypersensitivity, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.